InsidersTradesSigma
Devyser Diagnostics AB: directors' dealings · Finland · FIN-FSA
FI:devyser-diagnostics-abSE0016588867FI·FIN-FSAMcap 1.5Bn€Healthcare
Explore the full insider trade history of Devyser Diagnostics AB, a listed equity based in Finland. Shares trade on FI FI, under the oversight of FIN-FSA. Operating in the Healthcare sector, Devyser Diagnostics AB has published 5 insider filings. Market capitalisation: €1.5bn. The latest transaction was reported on 22 May 2026 — Purchase. Among the most active insiders: Mia Arnhult. The full history is free.
5
Insider Decl.
0
Thresholds
€195,171
5 ops.
Buy Volume
·
0 ops.
Sell Volume
Financial data
FY ended December 2025 · cache
90.10 €
Analyst consensus
3 analystsStrong buy
141.55 €Target 152.94 €(+70%)165.81 €
Income statement
Revenue250.5 M€
Gross profit201.9 M€81% margin
Net income−8.4 M€5.8% margin
Valuation
PER (trailing)100.1x
PER (forward)28.5x
P/Book4.2x
Beta0.82
Balance sheet & cash
Market cap1.51 Bn€
Total debt51.9 M€
Free Cash Flow−62.0 M€
Debt / Equity14%
Profitability & ownership
ROE4.4%
ROA4.7%
% insiders30.0%
% institutions47.7%
Last declaration on 22 May 2026
Declarations5 total
Executives●Purchase30FIN-FSA
€8,8201,000 shares@ €8.82040.0006% mcap18.4% of flow
Aktie
FI:A003Z012-1·
Ideal exit: 16 Feb 2027 (T+270)
Executives●Purchase20FIN-FSA
€1,286135 shares@ €9.52550.0001% mcap0.9% of flow
Aktie
FI:A003U153-1·
Ideal exit: 18 Aug 2026 (T+270)
Executives●Purchase29FIN-FSA
€140,63814,084 shares@ €9.98570.0093% mcap95.6% of flow
Aktie
FI:A003T495-1·
Ideal exit: 4 Aug 2026 (T+270)
Executives●Purchase36FIN-FSA
€39,1864,100 shares@ €9.55760.0026% mcap100.0% of flow
Aktie
FI:A003T388-1·
Ideal exit: 2 Aug 2026 (T+270)
Executives●Purchase13FIN-FSA
€5,240500 shares@ €10.47980.0003% mcap3.6% of flow
Aktie
FI:A003M385-1·
Ideal exit: 5 Dec 2025 (T+270)
5 of 5 declarations